• This ESMO–EURACAN Clinical Practice Guideline provides key recommendations for managing salivary gland cancer. • The guideline covers clinical and pathological diagnosis, staging and risk assessment, treatment and follow-up. • Treatment algorithms for parotid, submandibular, sublingual and minor salivary gland cancer are provided. • The author group encompasses a multidisciplinary group of experts from different institutions and countries in Europe. • Recommendations are based on available scientific data and the authors’ collective expert opinion.

Department of Head and Neck Oncology and Surgery Antoni van Leeuwenhoek Ziekenhuis and Amsterdam UMC Amsterdam

Department of Medical Oncology Radboud University Medical Center Nijmegen The Netherlands; Multidisciplinary Salivary Gland Society Geneva Switzerland https twitter com myESMO

Department of Otorhinolaryngology Head and Neck Surgery Erasmus University Medical Center Rotterdam The Netherlands

Department of Otorhinolaryngology Head and Neck Surgery Sorbonne Université Hôpital Tenon Assistance Publique Hôpitaux de Paris Paris France

Department of Pathology CHU Montpellier Montpellier France

Department of Pathology Radboud University Medical Center Nijmegen The Netherlands

Department of Radiology ASST Spedali Civili Brescia University of Brescia Brescia Italy

Evaluative Epidemiology Department of Research Fondazione IRCSS Istituto Nazionale dei Tumori Milan Italy

Faculty of Medicine Philipps University Marburg Marburg; Department of Radiation Oncology University Hospitals Gießen and Marburg Ltd Gießen Germany

Head and Neck Department Gustave Roussy Paris; French Network for Rare Head and Neck Cancers Paris France

Head and Neck Medical Oncology Unit Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy

Multidisciplinary Salivary Gland Society Geneva Switzerland; Department of Oncology Section Head and Neck Oncology KU Leuven Leuven; Department of Otorhinolaryngology Head and Neck Surgery University Hospitals Leuven Leuven Belgium

Multidisciplinary Salivary Gland Society Geneva Switzerland; Department of Pathology Charles University Faculty of Medicine in Plzen Plzen Czech Republic

Multidisciplinary Salivary Gland Society Geneva Switzerland; Department of Radiotherapy University Medical Center Utrecht The Netherlands

Salivary Gland Cancer UK London UK

Service d'Oncologie Médicale Institut Roi Albert 2 Cliniques Universitaires Saint Luc Brussels; Institut de Recherche Clinique et Expérimentale Université Catholique de Louvain Brussels Belgium

Erratum v

ESMO Open. 2023 Oct;8(5):101630. doi: 10.1016/j.esmoop.2023.101630. PubMed

Zobrazit více v PubMed

Ferlay J., Ervik M., Lam F., et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. https://gco.iarc.fr/today Available at.

RARECARENet. Information Network on Rare Cancers. http://rarecarenet.istitutotumori.mi.it/ Available at.

Radoi L., Barul C., Menvielle G., et al. Risk factors for salivary gland cancers in France: results from a case-control study, the ICARE study. Oral Oncol. 2018;80:56–63. PubMed

Lin H.H., Limesand K.H., Ann D.K. Current state of knowledge on salivary gland cancers. Crit Rev Oncog. 2018;23(3-4):139–151. PubMed PMC

Cong X. Air pollution from industrial waste gas emissions is associated with cancer incidences in Shanghai, China. Environ Sci Pollut Res Int. 2018;25(13):13067–13078. PubMed

Sawabe M., Ito H., Takahara T., et al. Heterogeneous impact of smoking on major salivary gland cancer according to histopathological subtype: a case-control study. Cancer. 2018;124(1):118–124. PubMed

Boukheris H., Curtis R.E., Land C.E., et al. Incidence of carcinoma of the major salivary glands according to the WHO classification, 1992 to 2006: a population-based study in the United States. Cancer Epidemiol Biomarkers Prev. 2009;18(11):2899–2906. PubMed PMC

Alvi S., Chudek D., Limaiem F. StatPearls Publishing; Island, FL: 2020. Cancer, Parotid. Treasure. PubMed

Bradley P.J., McGurk M. Incidence of salivary gland neoplasms in a defined UK population. Br J Oral Maxillofac Surg. 2013;51(5):399–403. PubMed

Gatta G., Capocaccia R., Botta L., et al. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet – a population-based study. Lancet Oncol. 2017;18(8):1022–1039. PubMed

El Naggar A.K., Chan J.K., Grandis J.R., et al. 4th ed. IARC Press; Lyon, France: 2017. World Health Organization (WHO) Classification of Head and Neck Tumours.

Faquin W., Rossi E.D. Springer; New York, NY: 2018. The Milan System for Reporting Salivary Gland Cytopathology.

Farahani S.J., Baloch Z. Retrospective assessment of the effectiveness of the Milan system for reporting salivary gland cytology: a systematic review and meta-analysis of published literature. Diagn Cytopathol. 2019;47(2):67–87. PubMed

Kim B.Y., Hyeon J., Ryu G., et al. Diagnostic accuracy of fine needle aspiration cytology for high-grade salivary gland tumors. Ann Surg Oncol. 2013;20(7):2380–2387. PubMed

Howlett D.C., Triantafyllou A. Evaluation: fine needle aspiration cytology, ultrasound-guided core biopsy and open biopsy techniques. Adv Otorhinolaryngol. 2016;78:39–45. PubMed

Cho J., Kim J., Lee J.S., et al. Comparison of core needle biopsy and fine-needle aspiration in diagnosis of malignant salivary gland neoplasm: systematic review and meta-analysis. Head Neck. 2020;42(10):3041–3050. PubMed

Romano E.B., Wagner J.M., Alleman A.M., et al. Fine-needle aspiration with selective use of core needle biopsy of major salivary gland tumors. Laryngoscope. 2017;127(11):2522–2527. PubMed

Ihrler S., Agaimy A., Guntinas-Lichius O., et al. Why is the histomorphological diagnosis of tumours of minor salivary glands much more difficult? Histopathology. 2021;79(5):779–790. PubMed

Seethala R.R. An update on grading of salivary gland carcinomas. Head Neck Pathol. 2009;3(1):69–77. PubMed PMC

Skalova A., Stenman G., Simpson R.H.W., et al. The role of molecular testing in the differential diagnosis of salivary gland carcinomas. Am J Surg Pathol. 2018;42(2):e11–e27. PubMed

O'Sullivan B. In: UICC TNM Classification of Malignant Tumours. 8th ed. Brierley J.D., Gospodarowicz M.K., Wittekind C., editors. Wiley-Blackwell; Oxford, UK: 2017. Major salivary glands.

Lombardi D., Tomasoni M., Paderno A., et al. The impact of nodal status in major salivary gland carcinoma: a multicenter experience and proposal of a novel N-classification. Oral Oncol. 2021;112 PubMed

Seethala R.R., Altemani A., Ferris R.L., et al. Data set for the reporting of carcinomas of the major salivary glands: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting. Arch Pathol Lab Med. 2019;143(5):578–586. PubMed

Lombardi D., McGurk M., Vander Poorten V., et al. Surgical treatment of salivary malignant tumors. Oral Oncol. 2017;65:102–113. PubMed

Sood S., McGurk M., Vaz F. Management of salivary gland tumours: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016;130(S2):S142–S149. PubMed PMC

Dillon P.M., Chakraborty S., Moskaluk C.A., et al. Adenoid cystic carcinoma: a review of recent advances, molecular targets, and clinical trials. Head Neck. 2016;38(4):620–627. PubMed PMC

Renkonen S., Sayed F., Keski-Santti H., et al. Reconstruction of facial nerve after radical parotidectomy. Acta Otolaryngol. 2015;135(10):1065–1069. PubMed

Bollig C.A., Wang K., Llerena P., et al. National analysis of oropharyngeal salivary gland malignancies treated with transoral robotic surgery. Otolaryngol Head Neck Surg. 2022;166(5):886–893. PubMed

Hay A.J., Migliacci J., Karassawa Zanoni D., et al. Minor salivary gland tumors of the head and neck-Memorial Sloan Kettering experience: incidence and outcomes by site and histological type. Cancer. 2019;125(19):3354–3366. PubMed PMC

Goel A.N., Badran K.W., Braun A.P.G., et al. Minor salivary gland carcinoma of the oropharynx: a population-based analysis of 1426 patients. Otolaryngol Head Neck Surg. 2018;158(2):287–294. PubMed

Han M.W., Cho K.J., Roh J.L., et al. Patterns of lymph node metastasis and their influence on outcomes in patients with submandibular gland carcinoma. J Surg Oncol. 2012;106(4):475–480. PubMed

Aro K., Tarkkanen J., Saat R., et al. Submandibular gland cancer: specific features and treatment considerations. Head Neck. 2018;40(1):154–162. PubMed

Vander Poorten V.L., Balm A.J., Hilgers F.J., et al. Prognostic factors for long term results of the treatment of patients with malignant submandibular gland tumors. Cancer. 1999;85(10):2255–2264. PubMed

International Head and Neck Scientific Group Cervical lymph node metastasis in adenoid cystic carcinoma of the major salivary glands. J Laryngol Otol. 2017;131(2):96–105. PubMed

Yoo S.H., Roh J.L., Kim S.O., et al. Patterns and treatment of neck metastases in patients with salivary gland cancers. J Surg Oncol. 2015;111(8):1000–1006. PubMed

Stennert E., Kisner D., Jungehuelsing M., et al. High incidence of lymph node metastasis in major salivary gland cancer. Arch Otolaryngol Head Neck Surg. 2003;129(7):720–723. PubMed

Guzzo M., Locati L.D., Prott F.J., et al. Major and minor salivary gland tumors. Crit Rev Oncol Hematol. 2010;74(2):134–148. PubMed

Klussmann J.P., Ponert T., Mueller R.P., et al. Patterns of lymph node spread and its influence on outcome in resectable parotid cancer. Eur J Surg Oncol. 2008;34(8):932–937. PubMed

Ali S., Palmer F.L., DiLorenzo M., et al. Treatment of the neck in carcinoma of the parotid gland. Ann Surg Oncol. 2014;21(9):3042–3048. PubMed

Armstrong J.G., Harrison L.B., Thaler H.T., et al. The indications for elective treatment of the neck in cancer of the major salivary glands. Cancer. 1992;69(3):615–619. PubMed

Frankenthaler R.A., Byers R.M., Luna M.A., et al. Predicting occult lymph node metastasis in parotid cancer. Arch Otolaryngol Head Neck Surg. 1993;119(5):517–520. PubMed

Regis De Brito Santos I., Kowalski L.P., Cavalcante De Araujo V., et al. Multivariate analysis of risk factors for neck metastases in surgically treated parotid carcinomas. Arch Otolaryngol Head Neck Surg. 2001;127(1):56–60. PubMed

Stenner M., Molls C., Luers J.C., et al. Occurrence of lymph node metastasis in early-stage parotid gland cancer. Eur Arch Otorhinolaryngol. 2012;269(2):643–648. PubMed

Kawata R., Koutetsu L., Yoshimura K., et al. Indication for elective neck dissection for N0 carcinoma of the parotid gland: a single institution’s 20-year experience. Acta Otolaryngol. 2010;130(2):286–292. PubMed

Lau V.H., Aouad R., Farwell D.G., et al. Patterns of nodal involvement for clinically N0 salivary gland carcinoma: refining the role of elective neck irradiation. Head Neck. 2014;36(10):1435–1439. PubMed

Vander Poorten V., Triantafyllou A., Thompson L.D., et al. Salivary acinic cell carcinoma: reappraisal and update. Eur Arch Otorhinolaryngol. 2016;273(11):3511–3531. PubMed

Terhaard C.H., Lubsen H., Rasch C.R., et al. The role of radiotherapy in the treatment of malignant salivary gland tumors. Int J Radiat Oncol Biol Phys. 2005;61(1):103–111. PubMed

Chen A.M., Garcia J., Lee N.Y., et al. Patterns of nodal relapse after surgery and postoperative radiation therapy for carcinomas of the major and minor salivary glands: what is the role of elective neck irradiation? Int J Radiat Oncol Biol Phys. 2007;67(4):988–994. PubMed

Herman M.P., Werning J.W., Morris C.G., et al. Elective neck management for high-grade salivary gland carcinoma. Am J Otolaryngol. 2013;34(3):205–208. PubMed

Zbaren P., Schupbach J., Nuyens M., et al. Elective neck dissection versus observation in primary parotid carcinoma. Otolaryngol Head Neck Surg. 2005;132(3):387–391. PubMed

Nobis C.P., Rohleder N.H., Wolff K.D., et al. Head and neck salivary gland carcinomas--elective neck dissection, yes or no? J Oral Maxillofac Surg. 2014;72(1):205–210. PubMed

Olsen K.D., Moore E.J. Deep lobe parotidectomy: clinical rationale in the management of primary and metastatic cancer. Eur Arch Otorhinolaryngol. 2014;271(5):1181–1185. PubMed

Vander Poorten V., Hunt J., Bradley P.J., et al. Recent trends in the management of minor salivary gland carcinoma. Head Neck. 2014;36(3):444–455. PubMed

Hellquist H., Skalova A., Barnes L., et al. Cervical lymph node metastasis in high-grade transformation of head and neck adenoid cystic carcinoma: a collective international review. Adv Ther. 2016;33(3):357–368. PubMed PMC

Atallah S., Moya-Plana A., Malard O., et al. Should a neck dissection be performed on patients with cN0 adenoid cystic carcinoma? A REFCOR propensity score matching study. Eur J Cancer. 2020;130:250–258. PubMed

Ellis M.A., Graboyes E.M., Day T.A., et al. Prognostic factors and occult nodal disease in mucoepidermoid carcinoma of the oral cavity and oropharynx: an analysis of the National Cancer Database. Oral Oncol. 2017;72:174–178. PubMed PMC

Roh J.L., Choi S.H., Lee S.W., et al. Carcinomas arising in the submandibular gland: high propensity for systemic failure. J Surg Oncol. 2008;97(6):533–537. PubMed

Halperin E.C., Wazer D.E., Perez C.A., Brady L.W., editors. Perez & Brady’s Principles and Practice of Radiation Oncology. 7th ed. Wolters Kluwer Health; Philadelphia, PA: 2018. Salivary glands.

Armstrong K., Ward J., Hughes N.M., et al. Guidelines for clinical target volume definition for perineural spread of major salivary gland cancers. Clin Oncol (R Coll Radiol) 2018;30(12):773–779. PubMed

Cheraghlou S., Kuo P., Mehra S., et al. Adjuvant therapy in major salivary gland cancers: analysis of 8580 patients in the National Cancer Database. Head Neck. 2018;40(7):1343–1355. PubMed

Mifsud M.J., Tanvetyanon T., McCaffrey J.C., et al. Adjuvant radiotherapy versus concurrent chemoradiotherapy for the management of high-risk salivary gland carcinomas. Head Neck. 2016;38(11):1628–1633. PubMed

Gebhardt B.J., Ohr J.P., Ferris R.L., et al. Concurrent chemoradiotherapy in the adjuvant treatment of high-risk primary salivary gland malignancies. Am J Clin Oncol. 2018;41(9):888–893. PubMed PMC

Amini A., Waxweiler T.V., Brower J.V., et al. Association of adjuvant chemoradiotherapy vs radiotherapy alone with survival in patients with resected major salivary gland carcinoma: data from the National Cancer Data Base. JAMA Otolaryngol Head Neck Surg. 2016;142(11):1100–1110. PubMed

Cerda T., Sun X.S., Vignot S., et al. A rationale for chemoradiation (vs radiotherapy) in salivary gland cancers? On behalf of the REFCOR (French rare head and neck cancer network) Crit Rev Oncol Hematol. 2014;91(2):142–158. PubMed

Pelak M.J., Walser M., Bachtiary B., et al. Clinical outcomes of head and neck adenoid cystic carcinoma patients treated with pencil beam-scanning proton therapy. Oral Oncol. 2020;107 PubMed

Vischioni B., Dhanireddy B., Severo C., et al. Reirradiation of salivary gland tumors with carbon ion radiotherapy at CNAO. Radiother Oncol. 2020;145:172–177. PubMed

Hayashi K., Koto M., Ikawa H., et al. Feasibility of re-irradiation using carbon ions for recurrent head and neck malignancies after carbon-ion radiotherapy. Radiother Oncol. 2019;136:148–153. PubMed

Jensen A.D., Poulakis M., Nikoghosyan A.V., et al. Re-irradiation of adenoid cystic carcinoma: analysis and evaluation of outcome in 52 consecutive patients treated with raster-scanned carbon ion therapy. Radiother Oncol. 2015;114(2):182–188. PubMed

Lok B.H., Jiang G., Gutiontov S., et al. Palliative head and neck radiotherapy with the RTOG 8502 regimen for incurable primary or metastatic cancers. Oral Oncol. 2015;51(10):957–962. PubMed PMC

Al-mamgani A., Tans L., Van rooij P.H., et al. Hypofractionated radiotherapy denoted as the “Christie scheme”: an effective means of palliating patients with head and neck cancers not suitable for curative treatment. Acta Oncol. 2009;48(4):562–570. PubMed

Girelli L., Locati L., Galeone C., et al. Lung metastasectomy in adenoid cystic cancer: is it worth it? Oral Oncol. 2017;65:114–118. PubMed

Locati L.D., Guzzo M., Bossi P., et al. Lung metastasectomy in adenoid cystic carcinoma (ACC) of salivary gland. Oral Oncol. 2005;41(9):890–894. PubMed

Bobbio A., Copelli C., Ampollini L., et al. Lung metastasis resection of adenoid cystic carcinoma of salivary glands. Eur J Cardiothorac Surg. 2008;33(5):790–793. PubMed

Bergamini C., Cavalieri S., Cascella T., et al. Local therapies for liver metastases of rare head and neck cancers: a monoinstitutional case series. Tumori. 2021;107(3):188–195. PubMed

Franzese C., Ingargiola R., Tomatis S., et al. Metastatic salivary gland carcinoma: a role for stereotactic body radiation therapy? A study of AIRO-Head and Neck working group. Oral Dis. 2022;28(2):345–351. PubMed

Nam S.J., Roh J.L., Cho K.J., et al. Risk factors and survival associated with distant metastasis in patients with carcinoma of the salivary gland. Ann Surg Oncol. 2016;23(13):4376–4383. PubMed

Lassche G., van Boxtel W., Ligtenberg M.J.L., et al. Advances and challenges in precision medicine in salivary gland cancer. Cancer Treat Rev. 2019;80 PubMed

Terhaard C.H., Lubsen H., Van der Tweel I., et al. Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch Head and Neck Oncology Cooperative Group. Head Neck. 2004;26(8):681–692. PubMed

Alfieri S., Granata R., Bergamini C., et al. Systemic therapy in metastatic salivary gland carcinomas: a pathology-driven paradigm? Oral Oncol. 2017;66:58–63. PubMed

Chen Z., Chen J., Gu Y., et al. Aberrantly activated AREG-EGFR signaling is required for the growth and survival of CRTC1-MAML2 fusion-positive mucoepidermoid carcinoma cells. Oncogene. 2014;33(29):3869–3877. PubMed

Laurie S.A., Ho A.L., Fury M.G., et al. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncol. 2011;12(8):815–824. PubMed

Ferrarotto R., Wirth L.J., Muzaffar J., et al. 919MO ACCURACY a phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut) Ann Oncol. 2020;31(suppl 4):S663.

Kang E.J., Ahn M.J., Ock C.Y., et al. Randomized phase II study of axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma. Clin Cancer Res. 2021;27(19):5272–5279. PubMed

Vander Poorten V., Triantafyllou A., Skalova A., et al. Polymorphous adenocarcinoma of the salivary glands: reappraisal and update. Eur Arch Otorhinolaryngol. 2018;275(7):1681–1695. PubMed

Locati L.D., Perrone F., Losa M., et al. Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs) Oral Oncol. 2009;45(11):986–990. PubMed

Uijen M.J.M., Lassche G., van Engen-van Grunsven A.C.H., et al. Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: a systematic review. Cancer Treat Rev. 2020;89 PubMed

Boon E., van Boxtel W., Buter J., et al. Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: a nationwide case series of 35 patients in The Netherlands. Head Neck. 2018;40(3):605–613. PubMed PMC

Fushimi C., Tada Y., Takahashi H., et al. A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. Ann Oncol. 2018;29(4):979–984. PubMed PMC

van Boxtel W., Locati L.D., van Engen-van Grunsven A.C.H., et al. Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma. Eur J Cancer. 2019;110:62–70. PubMed

Takahashi H., Tada Y., Saotome T., et al. Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma. J Clin Oncol. 2019;37(2):125–134. PubMed

Li B.T., Shen R., Offin M., et al. Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): results from a phase II basket trial. J Clin Oncol. 2019;37(suppl 15):6001. PubMed PMC

Dalin M.G., Desrichard A., Katabi N., et al. Comprehensive molecular characterization of salivary duct carcinoma reveals actionable targets and similarity to apocrine breast cancer. Clin Cancer Res. 2016;22(18):4623–4633. PubMed PMC

Lin V.T.G., Nabell L.M., Spencer S.A., et al. First-line treatment of widely metastatic BRAF-mutated salivary duct carcinoma with combined BRAF and MEK inhibition. J Natl Compr Canc Netw. 2018;16(10):1166–1170. PubMed PMC

Xu B., Jungbluth A.A., Frosina D., et al. The immune microenvironment and expression of PD-L1, PD-1, PRAME and MHC I in salivary duct carcinoma. Histopathology. 2019;75(5):672–682. PubMed PMC

Cocco E., Scaltriti M., Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15(12):731–747. PubMed PMC

Drilon A., Laetsch T.W., Kummar S., et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731–739. PubMed PMC

Drilon A., Li G., Dogan S., et al. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC) Ann Oncol. 2016;27(5):920–926. PubMed PMC

Drilon A., Ou S.I., Cho B.C., et al. Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent-front mutations. Cancer Discov. 2018;8(10):1227–1236. PubMed

Solomon J.P., Linkov I., Rosado A., et al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol. 2020;33(1):38–46. PubMed PMC

Broski S.M., Johnson D.R., Packard A.T., et al. 18)F-fluorodeoxyglucose PET/computed tomography: head and neck salivary gland tumors. PET Clin. 2022;17(2):249–263. PubMed

Mateo J., Chakravarty D., Dienstmann R., et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) Ann Oncol. 2018;29(9):1895–1902. PubMed PMC

Cherny N.I., Dafni U., Bogaerts J., et al. ESMO-Magnitude of Clinical Benefit Scale version 1.1. Ann Oncol. 2017;28(10):2340–2366. PubMed

Dykewicz C.A. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis. 2001;33(2):139–144. PubMed

Gross P.A., Barrett T.L., Dellinger E.P., et al. Purpose of quality standards for infectious diseases. Infectious Diseases Society of America. Clin Infect Dis. 1994;18(3):421. PubMed